Skip to main content

Table 1 Clinical characteristics of all subjects participating in this study

From: Analysis of serum polyunsaturated fatty acid metabolites in allergic bronchopulmonary aspergillosis

 

ABPA (N = 12)

Asthma (N = 23)

HC (N = 12)

Sex (male/female)

7/5

11/12

5/7

Age (years)

48 (28–52)

35 (20–48)

41 (38–44)

Smoker/non-smoker

1/11

3/20

0/12

FVC (% pred)

86.80 (69.10–102.10)

96.20 (87.55–101.40)

NA

FEV1 (% pred)

72.00 (54.60–87.80)

87.30 (76.70–94.80)

NA

FEV1/FVC (%)

88.60 (81.10–97.90)

78.30 (69.60–83.50)

NA

FEF25–75%pred

54.60 (24.90–72.10)

55.00 (42.80–69.90)

NA

Sputum Eosinophils (%)

12.50 (6.05–40.00)

7.75 (0.75–21.13)

NA

Blood Eosinophils (%)

10.60 (7.00–21.45)

3.75 (2.93–4.58)

2.37 (1.33–3.33)**

Blood Eosinophils (*109/l)

0.92 (0.49–1.46)

0.22 (0.18–0.32)

0.15 (0.10–0.20)***□□

TIgE (kU/l)

2681.00 (1987.00–5000.00)

504.00 (147.00–735.00)**

42.47 (14.90–60.83)***□□

Af.sIgE (kU/l)

9.70 (2.57–21.55)

0.07 (0.04–0.72)**

0.02 (0.00–0.02)***□□

Using glucocorticoids/not

3/9

5/18

0/12

  1. Values are presented as medians [25–75 interquartile range]
  2. * P-values compared with ABPA patients: *P < 0.05, **P < 0.01, ***P < 0.001
  3. □P-values compared with asthma patients: □P < 0.05, □□P < 0.01, □□□P < 0.001
  4. ABPA Allergic bronchopulmonary aspergillosis, HC Healthy controls, FVC Forced vital capacity, FEV1 Forced expiratory volume in one second, FEF25–75% Forced expiratory flow from 25 to 75% of FVC, TIgE Total IgE, Af. Aspergillus fumigatus, NA Not available
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us